Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TMX-67 to Be Launched in Japan after Spring 2011
November 22, 2010
- Takeda Accelerates Investment in Bioventures
November 22, 2010
- Kaken: Artz Drives Sales, Profits
November 15, 2010
- Leuplin's Successor Enters PIII in the US: Takeda, Millennium
November 15, 2010
- Mochida: NHI Price Cuts Hit Business
November 15, 2010
- COP10 Adopts Nagoya Protocol
November 15, 2010
- Operating Profit Rate Up for 5 of Top Six Drug Wholesalers
November 15, 2010
- LATUDA Meets Efficacy Endpoints in 3rd PIII Trial
November 15, 2010
- Lurasidone Approval “Exceptionally Quick”: DSP President Tada
November 15, 2010
- Zyvox Shows Higher Success Rate than Vancomycin: Pfizer
November 15, 2010
- Kyorin Licenses KRP-203 for IBD to Novartis
November 15, 2010
- Regorafenib's Efficacy Not Dependent on K-RAS Mutation: Bayer
November 15, 2010
- Santen Committed to Recapturing Top Share in Glaucoma Market
November 15, 2010
- Study Group for Developmentof New Adjuvants Created
November 15, 2010
- Takeda's Business to Hit Bottom in FY2013: President Hasegawa
November 15, 2010
- Astellas Acquires Diannexin Assets from Alavita
November 15, 2010
- JPA, JACDS Work to Improve Members' Business Practices
November 15, 2010
- Astellas Expects Additional Sales of ¥56 Bil. from OSI in FY2014
November 15, 2010
- Astellas to Integrate 3 Production Subsidiaries
November 15, 2010
- JMA Opposed to “Healthcare Tourism”
November 15, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…